Zoledronic Acid Injection, Solution
Product Images NDC 25021-830

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Zoledronic Acid (NDC 25021-830). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zol0b 0023 01

Chemical structure of zoledronic acid, showing a heterocyclic ring with nitrogen atoms and phosphonic acid groups attached to a central carbon, as depicted in the molecular diagram.*

FDA Label Image

Zol0b 0023 02

Two bar graphs comparing zoledronic acid and risedronate over time in days. The left graph shows therapeutic response rates, and the right graph presents serum alkaline phosphatase (SAP) normalization rates. Zoledronic acid generally demonstrates higher response and SAP normalization percentages across measured time points (28, 63, 91, 182 days).*

FDA Label Image

Zol0b 0023 03

Label for Zoledronic Acid Injection 5 mg per 100 mL (0.05 mg/mL) intravenous solution by Sagent Pharmaceuticals. The label includes usage instructions, storage conditions, and composition details, noting it is sterile, preservative-free, and made in Switzerland. The container is free of natural rubber latex.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.